Ontario, Canada (CU)_ Glenmark Pharmaceuticals, a Mumbai-based pharma giant, and Canadian biotech company SaNOtize Research and Development Corp have partnered to develop, sell, and distribute the latest innovative Nitric Oxide Nasal Spray – NONS for COVID-19 treatment. Phase 3 clinical trials of the nasal spray are ongoing, following the guidelines of the CDSCO’s Subject Expert Committee (SEC).
The nasal spray will be launched in Indian market by the end of 2021 with the brand name FabiSpray following the completion of its phase-3 clinical trials. This nasal spray, in addition to India, will also be accessible in Singapore, Sri Lanka, Laos, Myanmar, Vietnam, Nepal, Taiwan, Brunei, Cambodia, Hong Kong, and Timor-Leste markets.
By eradicating the virus in the upper airways, this nasal spray…
